UroGen's Chief Medical Officer Sold $400,000 in Stock After a 191% Run

Transaction summary

Key questions

• What was the mechanics for this transaction?
  The merchantability was conducted nether a pre-established Rule 10b5-1 trading program adopted connected August 15, 2025, which provides for automated execution and represents the concluding transaction of that plan's schedule.

• What is the standard of the insider's remaining nonstop investment?
  Mark Schoenberg continues to clasp 119,763 mean shares directly.

• What fiscal discourse does UroGen Pharma Ltd. contiguous astatine this valuation?
  The biotechnology company, which develops solutions for urothelial and specialty cancers, reported trailing 12-month gross of $140.5 cardinal and a nett nonaccomplishment of $133.2 million.

• How does the existent marketplace capitalization comparison to the transaction level?
  The disposition occurred with the company's marketplace capitalization astatine $2.0 billion, pursuing a play of show wherever shares were priced astatine $40.23 arsenic of the July 9, 2026 marketplace close.

Company Overview

Company Snapshot

• UroGen Pharma develops and commercializes innovative solutions for urothelial and specialty cancers, with superior gross sources including Zusduri, a sustained-release mitomycin formulation for non-muscle invasive bladder cancer, and RTGel, a proprietary reverse thermal gelation hydrogel exertion platform.

• The institution operates a commercial-stage biotechnology concern exemplary focused connected bringing caller therapeutic formulations to market, generating gross done merchandise income portion continuing to put successful probe and improvement for pipeline expansion.

• UroGen's superior customers are urology and oncology specialists, with people markets encompassing patients with non-muscle invasive bladder crab and different urothelial malignancies requiring adjuvant chemotherapy and specialized attraction modalities.

UroGen Pharma is simply a commercial-stage biotechnology institution with a $2 cardinal marketplace capitalization, demonstrating important maturation momentum with a one-year banal appreciation of 191.31%. The institution has achieved meaningful gross standard astatine $140.5 cardinal TTM portion maintaining a focused pipeline strategy centered connected proprietary cause transportation technologies for underserved oncology indications. UroGen's competitory vantage derives from its proprietary RTGel level exertion and its established commercialized infrastructure for specialty crab therapeutics, positioning the institution arsenic a differentiated subordinate successful the niche urothelial crab attraction market.